The “no reflow” phenomenon following acute myocardial infarction: Mechanisms and treatment options  by Kaul, Sanjiv
RT
M
S
K
a
A
R
A
A
K
N
M
M
C
I
m
m
i
h
0Journal of Cardiology 64 (2014) 77–85
Contents lists available at ScienceDirect
Journal of Cardiology
journa l homepage: www.e lsev ier .com/ locate / j j cc
eview
he “no reﬂow” phenomenon following acute myocardial infarction:
echanisms and treatment options
anjiv Kaul (MD) ∗
night Cardiovascular Institute UHN-62, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA
r t i c l e i n f o
rticle history:
eceived 27 March 2014
ccepted 27 March 2014
vailable online 3 May 2014
eywords:
o reﬂow
yocardial contrast echocardiography
yocardial infarction
a b s t r a c t
If ‘no reﬂow’ is observed within 45min of reperfusion using balloon angioplasty or stent, it is probably
related to microthromboemboli, which may also contribute to the extension of the ‘no reﬂow’ zone by
converting ‘low reﬂow’ areas into necrotic ones even when reperfusion is achieved more than 45min
after the onset of coronary occlusion. Since ‘no reﬂow’ is noted when 45min of coronary occlusion has
elapsed even in the absence of a thrombus, ‘no reﬂow’ late after reperfusion is predominantly due to
tissue necrosis and unlikely to be resolved unless methods to reduce infarct size are used.
Attempts at reducing the intracoronary thrombus burden during a coronary procedure for acute
myocardial infarction (AMI) have been shown to reduce ‘no reﬂow’ and improve clinical outcome, as
has the use of potent antithrombotic agents. Drugs that can reduce infarct size, when given intracoro-
nary or intravenous in conjunction with a coronary intervention during AMI can also reduce ‘no reﬂow’
and improve outcomes in patients with AMI.
The prognostic importance of ‘no reﬂow’ post-AMI is related to its close correspondence with infarct
size. Although several imaging and non-imaging methods have been used to assess ‘no reﬂow’ or ‘low
reﬂow’ myocardial contrast echocardiography remains the ideal method for its assessment both in and
outside the cardiac catheterization laboratory.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.ontents
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ntroduction
Following reperfusion therapy, myocardial tissue perfusion
of myocardial tissue ‘no reﬂow’ in patients with AMI was ﬁrst
described by Ito et al. [1] and then conﬁrmed by several othersay not be restored in up to a third of the patients after acute
yocardial infarction (AMI) despite thrombolysis in myocardial
nfarction grade3ﬂowon coronary angiography. This phenomenon
∗ Tel.: +1 503 494 8750; fax: +1 503 494 8550.
E-mail address: Kauls@ohsu.edu
ttp://dx.doi.org/10.1016/j.jjcc.2014.03.008
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights re[2–6] using myocardial contrast echocardiography (MCE). Later,
other imaging techniques also described the ﬁnding [7,8], but their
validity for accurately assessing ‘no reﬂow’ is questionable and will
be discussed later.Many clinicians believe that the ‘no reﬂow’ phenomenon
results solely from the micro-vascular obstruction caused by distal
embolization of thrombi and plaque components during balloon
angioplasty and stent placement. This review is meant to refute
served.
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his notion and to demonstrate that the ‘no reﬂow’ phenomenon
esults principally from tissue and microvascular damage during
yocardial ischemia and not from microembolization, particularly
f coronary occlusion persists beyond 45min. If the ischemic period
s short (<45min), infarction is likely to be minimal and if there is
no reﬂow’ after balloon angioplasty and stent placement, then it
an be attributed to distal embolization.
When coronary occlusion has lasted for >45min, the duration
f ischemia determines the likelihood and the extent of ‘no reﬂow’
ndependent of whether there is additional distal microemboliza-
ion. Furthermore, surrounding the ‘no reﬂow’ zone there is a
low reﬂow’ zone that can either survive as such or evolve into
‘no reﬂow’ area after reperfusion therapy. The size of the ‘low
eﬂow’ zone is principally determined by collateral blood ﬂow.
inally there are potential treatment options for the ‘no reﬂow’
henomenon.
istorical perspective
The ‘no reﬂow’ phenomenon was most probably ﬁrst reported
n 1959 in the kidney by Sheehan and Davis (the one of Sheehan’s
yndrome fame) [9]. The initial description in the heartwas byKrug
nd colleagues [10] who showed interstitial edema and red cell
acking of damaged capillaries. A year later, Majno and colleagues
11] reported their ﬁndings in the brain in a “Letter to the Editor”
n The Lancet and the histological ﬁndings they described are those
hat are nowdeemed characteristic of the ‘no reﬂow’ phenomenon.
hese ﬁndings were later conﬁrmed in the heart in much greater
etail by Kloner et al. [12] in 1974. The hallmarks of the ‘no reﬂow’
henomenon initially described by these authors are myocyte
welling, endothelial cell swelling with luminal protusions, and
ntravascular red blood cell aggregates [11,12]. Later ﬁndings
ncluded presence of capillary leukocyte plugging [13,14] and to a
esser extent, platelet and ﬁbrin accumulation [15,16]. Myocardial
amage always precedes the microvascular abnormalities in the
ig. 1. Panel A illustrates a four-chamber view depicting three different contrast pattern
n whom microbubbles were injected into the left main coronary artery in the cardia
=homogeneous opaciﬁcation. These regions have been magniﬁed to show a score of 0 in
unction fully after balloon angioplasty. Those with scores of 0.5 improved function parti
ource: From Ragosta et al. [2] with permission of the American Heart Association.gy 64 (2014) 77–85
presence of total coronary occlusion not caused by a coronary
thrombus and not vice versa [17].
Despite abundant basic science literature indicating that ‘no
reﬂow’ occurs within minutes after release of total coronary
occlusion, no attempts were made to study this phenomenon
in humans in the early days of thrombolysis and balloon angio-
plasty for AMI. This was partly related to the lack of methods
for and interest in assessing microvascular perfusion either out-
side or in the cardiac catheterization laboratory. Routinely used
clinical techniques to assess myocardial perfusion at that time
such as single photon emission tomography were thought to
measuremyocyte integrity, but not provide an independent assess-
ment of microvascular perfusion. Ito and colleagues [1] were
able to assess the ‘no reﬂow’ phenomenon after AMI in humans
by using MCE, a technique that utilizes gas-ﬁlled microbub-
bles, which after intravascular administration remain entirely
within the intravascular space and on ultrasound examination
can delineate regions with and without microvascular perfusion
[18,19]. Earlier studies used intra-coronary injections of microbub-
bles in the cardiac catheterization laboratory (Fig. 1) [1,2]. With
the advent of commercially available microbubbles capable of
trans-pulmonary passage, it became possible to assess myocardial
perfusion with intravenous administration of these agents (Fig. 2)
[4–6,20].
Myocardial blood ﬂow in reperfused myocardium
In theabsenceof any tissuedamage, restorationof coronaryﬂow
after prolonged coronary occlusion results in hyperemic myocar-
dial blood ﬂow (MBF). At this stage, because of the release of
endogenous adenosine and other vasodilators during ischemia, the
resistance vessels within the myocardium are fully dilated, result-
ing in reduced microvascular resistance and increased MBF. The
hyperemia under these conditions is limited principally by the cap-
illary number, size, and function [21–23]. Since the hallmark of
s in a patient with an antero-apical infarction and a patient infarct-related artery
c catheterization laboratory: 0 =no opaciﬁcation; 0.5 =patchy opaciﬁcation; and
panel B and scores of 0.5 and 1 in panel C. Regions with scores of 1 improved their
ally and those with scores of 0 did not improve function.
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zone also changes dynamically in the ﬁrst several hours after
reperfusion because of vasospasm, myocardial edema, etc. [24,29].
Panels A and B in Fig. 3 show relatively small perfusion defects
at 45min and 3h after reperfusion in an infarct model, while theig. 2. Myocardium perfusion defect in a patient with chest pain and no electrocard
nd panel B depicts a small area of residual ‘no reﬂow’ in the apex that did not imp
ource: From Kaul S. [20], with permission from the American Heart Association.
he ‘no reﬂow’ phenomenon is capillary damage, the ﬂow within
he center of this area where the damage is most dense (mostly
he endocardium) can be reduced compared to the normal bed. In
reas of less dense damage, the hyperemic ﬂow may be attenuated
nough to be similar to or even higher than in normal tissue that is
ot experiencing hyperemia. In the ‘low reﬂow’ zone surrounding
t, the actual ﬂow is hyperemic [24–30], although not as high as
ould be expected in the normally hyperemic tissue.
This is important because if one performs MCE immediately
fter reperfusion one might underestimate the size of the ‘no
eﬂow’ and ‘low reﬂow’ zones [24–26]. The size of the ‘no reﬂow’
ig. 3. Changes in perfusion patterns after reperfusion in a dog with a nearly trans-
ural infarction caused by 3h of coronary occlusion. After 45min of reperfusion, a
mall relative color defect localized to the endocardium in the anterior wall is noted
s shownby arrows in panel A. After 3h of reperfusion, this defectwas slightly larger
s depicted by arrows in panel B. The addition of dipyridamole, resulted in a much
arger relative contrast defect shown by arrows in panel C which closely delineated
he true size and shape of the infarct on tissue staining with triphenyl tetrazolium
hloride, which is indicated by arrows in panel D.
ource: From Villanueva et al. [24], with permission of the American Heart Associa-
ion.hic changes before (A) and after (B) coronary angioplasty. Panel A depicts risk area
nction one month later.Fig. 4. The temporal sequence of perfusion defects deﬁned by myocardial con-
trast echocardiography in 21 dogs undergoing 3h of coronary occlusion followed
by reperfusion. The y-axis depicts perfusion defect size as a percentage of the left
ventricularmyocardium in the short-axis slice,while the x-axis represents the inter-
val after the onset of reperfusion, except the last stage (DP – dipyridamole) which
could have followed either a 2-h (4 dogs) or a 3-h period of reperfusion (17 dogs).
Source: From Villanueva et al. [24], with permission of the American Heart Associa-
tion.
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nfract size measured at 3h is signiﬁcantly larger. Fig. 4 illus-
rates perfusion defect sizes from a large group of dogs undergoing
schemia followed by reperfusion. It is clear that the defect sizes at
est change dynamically between 15min and 3h after reperfusion.
lthough no clinical study has measured the ‘no reﬂow’ zone at
epeated intervals after AMI, the ideal time to measure ‘no reﬂow’
t rest in order to determine the extent of myocardial necrosis is
robably after48h following reperfusion [30]. At that timedynamic
hanges in resting tissue perfusion have subsided and the extent of
o reﬂow correlates well with infarct size and denotes a region
f irreversible tissue damage. Also any transient contribution of
icrothromboemboli to the ‘no reﬂow’ zone have reversed by that
ime.
Since the ischemic zone that will ultimately demonstrate ‘no
eﬂow’ has reduced MBF reserve immediately after reperfusion
24–26,31–33], administration of a vasodilator such as dipyri-
amole unmasks the regions of abnormal ﬂow reserve that will
ltimately develop necrosis and no reﬂow [24,25]. Panel C in Fig. 3
ig. 5. The temporal sequence of radiolabeled microsphere-derived transmural
lood ﬂow within the risk area in 21 dogs undergoing 3h of coronary occlusion
ollowed by reperfusion. Transmural blood ﬂow within the risk area is expressed as
percent of transmural blood ﬂow in the normal posterior wall on the y-axis and
he interval after reperfusion is depicted on the x-axis. DP representsmeasurements
ade during the infusion of dipyridamole after 3h of reﬂow.
ource: From Villanueva et al. [24], with permission of the American Heart Associa-
ion.
Fig. 6. (A) Relation between myocardial contrast echocardiography (MCE) defect
size 15min after reperfusion in the absence of adenosine (y-axis) and infarct size (y-
axis) measured either at 15min (ﬁlled circles) or 3h after reperfusion (open circles).
(B) Relation between MCE defect size 15min after reperfusion in the presence of
adenosine (x-axis) and infarct size (y-axis) measured either at 15min (ﬁlled circles)
or 3h after reperfusion (open circles).
Source: From Villanueva et al. [25], with permission of the American Heart Associa-
tion.
illustrates the perfusion bed size at 3h after reperfusion during
administration of dipyridamole. In comparison to panels A and B in
the same ﬁgure, the defect size closely approximates the infarct
size (panel D) [24] and this corresponds to the increase in per-
fusion defect size after administration of dipyridamole (panel B in
Fig. 4). The obvious increase in defect size is related to the relative
hypoperfusion within the infarct bed compared to the normal bed
caused by dipyridamole and not an absolute decrease in MBF. Fig. 5
depicts MBF (measured with radiolabeled microspheres) within
the reperfused myocardium compared to the normal myocardium,
highlighting the heterogeneity in MBF during the ﬁrst 3h of reper-
fusion. In the presence of dipyridamole the heterogeneity in MBF
as well as MBF compared to the normal bed are both markedly
reduced allowing delineation of the ‘no reﬂow and low reﬂow’
zones.
The examples shown above are in the presence of dipyridamole
3h after reperfusion, but the same results can be obtained immedi-
ately after reperfusion [25]. Fig. 6 illustrates the relation between
actual infarct size and perfusion defect size on MCE at both 15min
and 3h after reperfusion. Panel A shows the marked underestima-
tion of infarct size by the perfusion defect size in the absence of
dipyridamole, while panel B shows the results after dipyridamole
administration. Therefore, with dipyridamole the perfusion defect
size predicts infarct size accurately no matter when it is measured
after reperfusion.Inﬂuence of collateral blood ﬂow
Since ‘no reﬂow’ occurs exclusively within the infarcted tis-
sue, its extent as that of the infarction is determined by the level
S. Kaul / Journal of Cardiology 64 (2014) 77–85 81
Fig. 7. Short-axis viewof a patientwith a totally occluded right coronary artery after
acute myocardial infarction. The upper panel depicts a myocardial contrast echo-
cardiography image after microbubble injection into the left main coronary artery
prior to angioplasty of the right coronary artery showing contrast enhancement of
the entire left ventricular myocardium. The bottom panel depicts the same view
after successful angioplasty of the right coronary artery and injection of microbub-
bles directly into it, showing the perfusion bed of the right coronary artery. At the
time of coronary occlusion this bed was supplied by collaterals from the left system
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Fig. 8. Panel A shows the ultrasound beam elevation (thickness) represented as
‘E’ in A. If all the microbubbles in the elevation are destroyed by a single pulse
of ultrasound at t0, then replenishment of the beam elevation (d1–d4, B–E), will
depend on the velocity of microbubbles and time of imaging. Panel B shows the
pulsing interval (x-axis) versus video-intensity (y-axis) plotwheremyocardial blood
volume is shown as A and rate of microbubble replenishment is shown as ˇ. The
function used to ﬁt the relation is also depicted.
Fig. 9. Perfusion defects at various times after microbubble destruction and the
ultimate infarct size (by tissue staining) in a dog undergoing 6h of left anterior
descending artery occlusion. In this example, although the risk area (A) is large at
2.7 s after bubble destruction, the infarct size on post-mortem tissue staining is
moderate because of modest collateral-derived myocardial blood ﬂow (D). The epi-
cardium is spared fromnecrosis and the infarct size is accurately predicted at 30min
after coronary occlusion at 8.7 s after microbubble destruction (C), where assess-top panel).
ource: From Sabia et al. [34], with permission of the New England Medical Society.
f nutrient MBF at the time of coronary occlusion. Hence, col-
ateral blood ﬂow is a major determinant of the size of the ‘no
eﬂow’ zone. Consequently, MCE performed at the time of coro-
ary occlusion can predict the ultimate size of ‘no reﬂow’ even if
he coronary occlusion is not reversed. In the early days ofMCE, col-
ateral ﬂow was measured by injecting microbubbles directly into
on-occluded coronary arteries. The top panel in Fig. 7 is an exam-
le of a patient with an inferior AMI and occluded right coronary
rtery who demonstrates adequate myocardial perfusion after left
ain injection of microbubbles. After the artery was opened and
icrobubbles were injected directly into it (bottom panel), there
as no evidence of ‘no reﬂow’ in the previously occluded bed [34].
After introduction of commercially available microbubbles
apable of myocardial opaciﬁcation from a peripheral venous
njection, it became possible to quantify MBF with MCE. For this
pproach a dilute solution of microbubbles is administered intra-
enously as a constant infusion using a pump device. In a few
inutes, steady state is achieved, when the concentration of
icrobubbles in the myocardium and other organs is constant.
hen high-energy ultrasound is used to destroy microbubbles in
he myocardium after which their rate of myocardial replenish-
ent is measured (Fig. 8 Panel A). Time versus acoustic intensity
AI) curves can be generated from different myocardial regions and
tted to an exponential function: y=A(1− e−ˇt), where y is AI at
pulsing interval t, A is the plateau AI, and ˇ is the rate constant
hich represents the rate of rise of AI (and thus mean microbubble
elocity, Fig. 8, Panel B) [35].
The beamwidth of anultrasoundprobe represents the thickness
f the ultrasound image and is approximately 5mm. Microbubbles,
hich have an intravascular rheology similar to that of erythro-
ytes [36,37], travel at 1mms−1 at rest within the myocardial
apillaries. Thus, after microbubble destruction, the beam width
llswithin 5 s in the presence of normalMBF.WhenMBF is reduced
t takes a longer time to ﬁll the beam and the time it takes to ﬁll
he beam is inversely proportional to MBF. Myocardial tissue is
ment of epicardial perfusion is slightly better that at 4.4 s after bubble destruction
(B) because of more collateral ﬁlling.
Source: From Coggins et al. [40], with permission of the American Heart Association.
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nlikely to undergo necrosis if MBF is >0.25mLmin−1 g−1 (normal
eing 1mLmin−1 g−1) [38,39]. Thus, we can deﬁne the amount and
xtent of collateral MBF that is likely to prevent myocardial necro-
is and ‘no reﬂow’ by measuring the time it takes to ﬁll an occluded
yocardial bed.
Fig. 9 is an example of MCE images at various times after
icrobubble destruction. Although the region with reduced per-
usion is delineated 2.7 s after bubble destruction, the ﬁnal size
f perfusion defect at 8.7 s is much smaller because of collat-
ral ﬂow with the margins and epicardium, and the infarct size
panel D) corresponds to the perfusion defect size at this time [40].
hese imageswere taken 30min after coronary occlusionwhile the
nfarct size was measured 6h after occlusion. Thus the ultimate
nfarct size (and thus ‘no reﬂow’ area) was predicted at the time
f coronary occlusion. This obviously has great potential import
n clinical decision-making, including urgency of providing reper-
usion options.
onversion of ‘low reﬂow’ to ‘no reﬂow’
Aspreviously stated, there is a ‘low reﬂow’ zone surrounding the
no reﬂow’ zone. The ‘no reﬂow’ zone exists even in the absence of
eperfusion and its spatial extent is determined by the absence of
dequate collateral bloodﬂow.However, after reperfusion, the ‘low
eﬂow’ zone can either persist as viable myocardium or become
ubject to necrosis. The fate of this ‘low reﬂow’ zone after reper-
usion is determined either by thedegree of persistentmicroemboli
rom the thrombus/plaque in regions undergoing stent placement
nd/or from reperfusion injury.
In an animal model where coronary thrombosis was produced
nd then the thrombus was labeled with a 99mTc agent, it was
bserved that microthromboembolism occurred during balloon
ngioplasty [41,42]. The ‘no reﬂow’ zone was also larger in dogs
ith coronary thrombosis undergoing angioplasty than in those
imply undergoing coronary ligation [42]. The spatial extent of
icrothromboemboli assessed in these studies was larger than the
no reﬂow’ zone. This phenomenon is again related to collateral
essels. The microemboli that travel down a vessel will extend
eyond the risk area through collaterals [43]. Other investigators
ave also implicated microthromboemboli in the development of
no reﬂow’ phenomenon [44,45]. However, these results should be
onstrued with caution. While, as in our study, it is possible that
art of the initial ‘no reﬂow’ may be from microthromboemboli,
hese are most likely to dissipate with the use of thrombolytics and
ther anti-platelet therapy. Contrariwise, if cholesterol crystals and
ther debris are embolized peripherally during balloon angioplasty
nd stent placement, they may cause permanent microvascular
bstruction and contribute to the ‘no reﬂow’ phenomenon [46,47].
While the importance of reperfusion injury in inﬂuencing the
ltimate infarct size remains controversial [48], it is possible that
he ‘low reﬂow’ zones are more susceptible to injury and may
ndergo necrosis after reperfusion compared to normally perfused
egions. This can result from additional myocardial edema, inﬂam-
ation, and leukocyte as well as platelet activation caused by the
elease of oxygen-free radicals. Whereas in our studies we did not
nd a reduction in resting MBF or increase in the ‘no reﬂow’ zone
p to 3h of reperfusion, others have reported the opposite [29,49].
hese discrepancies may result from the different animal models
sed. In dogs, there is abundant collateral ﬂow that might preserve
he ‘low reﬂow’ zone, while rabbits do not have this protection,
hich might explain a greater susceptibility to reperfusion injury
49].ther methods of assessing no reﬂow
Imaging techniques such as coronary angiography, cardiacmag-
etic resonance imaging (MRI), and cardiac computed tomographygy 64 (2014) 77–85
(CT) have been used to assess myocardial ‘no reﬂow’ [7,8]. Coro-
nary angiography was used because of its availability at the time
of coronary intervention and most laboratories did not have the
know-how to perform MCE studies. All these techniques use dyes
that do not remain within the intravascular space and thus cannot
in principle deﬁne the status of the microcirculation. On MRI for
example, the samearea that shows low ‘perfusion’ earlyafter reﬂow
(deemed the ‘no reﬂow’ zone’) shows hyper-enhancement several
minutes later because of dye extravasation into the extravascular
space where it gets lodged as a result of low perfusion. Coronary
angiography is alsoaplanar techniqueandcannotdetermine the3D
spatial extent ofmyocardial perfusion. The inferiority of other tech-
niques compared to MCE for assessing ‘no reﬂow’ was conﬁrmed
in a multicenter study [50].
The Doppler wire has also been used to characterize ‘no reﬂow.’
Studies in TIMI grade 2 patients, most of whom have no reﬂow,
show systolic ﬂow reversal, reduced anterograde systolic ﬂow,
and anterograde diastolic ﬂow with a rapid deceleration slope
[51]. Because of the reduced anterograde ﬂow and the presence
of ﬂow reversal, coronary inﬂow to the myocardium is reduced.
The Doppler wire, however, remains an indirect way to assess the
‘no reﬂow’ phenomenon.
Prognostic implications for the ‘no reﬂow’ phenomenon
Some literature suggests that the ‘no reﬂow’ zone is smaller than
the infarct zone, whereas our studies show that it corresponds to
infarct size. The differences can be attributed mostly to method-
ological factors. For example, if the model studied is total coronary
occlusion, then the infarct size is somewhat smaller than the ‘no
reﬂow’ zone. In our studies we measured the infarct size after
reperfusion, which is more relevant to the clinical situation. We
also measured the infarct size by tissue staining with triphenyl
tetrazolium chloride, while others performed a microscopic exam-
ination. In any case, there is a strong correlation between the size of
‘no reﬂow’ and that of infarction. As a consequence, the ‘no reﬂow’
zone size predicts systolic left ventricular function, remodeling,
infarct expansion, ventricular arrhythmias, and thus the outcome
[2–6,52–58].
Treatment options for ‘no reﬂow’
As stated previously, if during AMI the duration of ischemia is
<45min before reperfusion is attempted and there is the presence
of ‘no reﬂow’, it is most likely from distal thromboembolization. In
that instance, any maneuver to reduce microthromboemboli will
reduce ‘no reﬂow’. In addition, if the microthromboemboli con-
tribute to the conversion of the ‘low reﬂow’ zone to ‘no reﬂow’
even after longer duration of coronary occlusion, then reducing the
incidence or quantum of distal embolization will also reduce ‘no
reﬂow’. Therefore, randomized studies that have utilized manual
thrombus aspiration have shown better microvascular perfusion
and long-term outcome compared to control patients undergoing
a coronary intervention during AMI [59–62]. Similar results have
been obtained with a distal occlusive protection device not with a
thrombectomy device [62–64].
Other ways to reduce the thrombus burden can also have ben-
eﬁcial effects on microvascular perfusion. For example, routine
use of platelet inhibitors during coronary interventions for AMI
can beneﬁt myocardial perfusion; IIb/IIIa inhibitors, abciximab
and tiroﬁban are examples of such agents [65,66]. Intracoronary
administration of abciximab seems to have less ‘no reﬂow’ than
intravenous administration [65]. An investigational drug, CP-4715
that inhibits both IIb/IIIa and v3 has been shown to dramati-
cally reduce ‘no reﬂow’ and the infarct size in a canine coronary
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[ig. 10. Myocardial contrast echocardiography-derived ‘no reﬂow’ images from do
nd a v3 inhibitor) in a model of reperfusion after angioplasty of a thrombus-occ
ource: From Sakuma et al. [67] with permission of the European Society of Cardiol
hrombosis model undergoing balloon angioplasty (Fig. 10) [67].
he inhibition of v3 resulted in less inﬂammation, which
ay have contributed to less leukocyte plugging and less ‘no
eﬂow’.
Other than reducing distal thromboembolization, any maneu-
er that will reduce the infarct size will also reduce ‘no reﬂow,’
articularly if ischemia exceeds 45min. Thus pharmacological
nterventionswith adenosine (both intracoronary and intravenous)
68–70], nicorandil (intravenous and combination of intravenous
nd intracoronary) [71,72], and verapamil (intracoronary) [73,74]
ave all been shown to have salutary effects on the ‘no reﬂow’
ize. Whereas nitroprusside was shown in a pilot study [75] to
ave a beneﬁcial effect on ‘no reﬂow’ a randomized study failed
o demonstrate this effect [76].
Adenosine has been shown to reduce the infarct size prin-
ipally through coronary vasodilation and its anti-inﬂammatory
ffects through different adenosine receptors. Nicorandil reduces
alcium overload and inﬂammation, the latter through its anti-
xidant and neutrophil inhibiting properties. Verapamil reduces
ow heterogeneity in the ischemic bed and also inhibits platelets
hat can be activated due to low shear during ischemia. GP-531,
n investigational drug that has no basal effect but increases
denosine levels during ischemia, was also shown to reduce
he ‘no reﬂow’ zone and the infarct size in an animal model
77].
A recent animal study from Kloner’s group that has been active
n this ﬁeld for 40 years reported a decrease in ‘no reﬂow’ from
ypothermia late after reperfusion despite no change in the infarct
ize [78]. This intriguingﬁnding is contrary to their original concept
hat microvascular dysfunction during coronary occlusion results
rom tissue damage and not vice versa [17]. Studies in animal
odels other than rabbit using in vivo assessment of myocardial
erfusion will be needed to conﬁrm these ﬁndings. Obviously, if
yocardial cooling is instituted early during coronary occlusion,
t will reduce the infarct size and hence the size of the ‘no reﬂow’
one after reperfusion [79].
[
[eiving (A) saline, (B) tiroﬁban (a IIb/IIIa inhibitor), and (C) CP-4715 (both a IIb/IIIa
coronary artery.
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